뇌졸중에서 우울증과 실행기능부전에 대한 고찰 = Depression and Executive Dysfunction in Stroke

다국어 초록 (Multilingual Abstract)

Depression and executive dysfunction are common neuropsychiatric sequelae of stroke. Patients with stroke are more predisposed to depression and executive dysfunction compared to patients with similar degree of physical disability. Both depression and executive dysfunction are also associated with poor prognosis such as high mortality and delayed recovery after stroke. Complex neurobiological and anatomical mechanisms are associated with the development of depression and executive dysfunction after stroke. Activation of pro-inflammatory cytokines is thought to be associated with onset of depression, whereas injuries in frontal-subcortical circuit are thought to be a link between depression and executive dysfunction. Early detection of depressive symptoms and both pharmacological and non-pharmacological treatment would be helpful. In this review paper, the authors investigated 1) biological and neuroanatomical substrate for poststroke depression and executive dysfunction, 2) the relationship and common etiopathology for poststroke depression and executive dysfunction, and 3) pharmacological and non-pharmacological treatment for poststroke depression. The contents of the paper are as follows : the prevalence, clinical manifestation, and biological etiology for poststroke depression, neuroanatomical abnormalities as a common etiological factor for depression and executive dysfunction, pharmacotherapy and non-pharmacological approach.

참고문헌 (Reference)

1 Alexopoulos GS, "‘Vascular depression’ hypothesis" 54 : 915-922, 1997

2 Herrmann LL, "White matter hyperintensities in late life depression: a systematic review" 79 : 619-624, 2008

3 Dobos N, "The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation- induced depression" 28 : 905-915, 2012

4 Mohlman J, "The role of executive functioning in CBT: a pilot study with anxious older adults" 43 : 447-465, 2005

5 Walter M, "The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression" 66 : 478-486, 2009

6 Gabbay V, "The possible role of the kynurenine pathway in adolescent depression with melancholic features" 51 : 935-943, 2010

7 Nichols KK, "The international workshop on meibomian gland dysfunction: executive summary" 52 : 1922-1929, 2011

8 Maes M, "The inflammatory & neurodegenerative (I & ND) hypothesis of depression: leads for future research and new drug developments in depression" 24 : 27-53, 2009

9 Debette S, "The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis" 341 : c3666-, 2010

10 Alexopoulos GS, "Role of executive function in late-life depression" 64 (64): 18-23, 2003

11 Palomäki H, "Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy" 66 : 490-494, 1999

12 Almeida OP, "Preventing depression after stroke: Results from a randomized placebo-controlled trial" 67 : 1104-1109, 2006

13 Spalletta G, "Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness" 249 : 1541-1551, 2002

14 Robinson RG, "Poststroke depression: prevalence, diagnosis, treatment, and disease progression" 54 : 376-387, 2003

15 Robinson RG, "Poststroke depression: a review" 55 : 341-349, 2010

16 Broomfield NM, "Post-stroke depression: the case for augmented, individually tailored cognitive behavioural therapy" 18 : 202-217, 2011

17 Lenzi GL, "Post-stroke depression" 164 : 837-840, 2008

18 van Swieten JC, "Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. A morphometric correlation with arteriolosclerosis and dilated perivascular spaces" 114 (114): 761-774, 1991

19 O’Sullivan M, "Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis" 59 : 321-326, 2002

20 Pantoni L, "Pathogenesis of leukoaraiosis: a review" 28 : 652-659, 1997

21 Campbell JJ 3rd, "Neuropsychiatric significance of subcortical hyperintensity" 13 : 261-288, 2001

22 Loftis JM, "Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies" 37 : 519-533, 2010

23 Watkins CL, "Motivational interviewing early after acute stroke: a randomized, controlled trial" 38 : 1004-1009, 2007

24 Folstein MF, "Mood disorder as a specific complication of stroke" 40 : 1018-1020, 1977

25 나경세, "Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia" KARGER 56 (56): 55-63, 2007

26 Lyons KE, "Monitoring, metacognition, and executive function: elucidating the role of self-reflection in the development of self-regulation" 40 : 379-412, 2011

27 Frisoni GB, "Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome" 249 : 1423-1432, 2002

28 Vataja R, "Magnetic resonance imaging correlates of depression after ischemic stroke" 58 : 925-931, 2001

29 Vataja R, "Magnetic resonance imaging correlates of depression after ischemic stroke" 58 : 925-931, 2001

30 Greenwald BS, "MRI signal hyperintensities in geriatric depression" 153 : 1212-1215, 1996

31 Jokinen H, "Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study" 27 : 384-391, 2009

32 Bolla-Wilson K, "Lateralization of dementia of depression in stroke patients" 146 : 627-634, 1989

33 Smith J, "Information provision for stroke patients and their caregivers" CD001919-, 2008

34 Maes M, "Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms" 22 : 75-83, 2009

35 Miller AH, "Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression" 65 : 732-741, 2009

36 Cummings JL, "Frontal-subcortical circuits and human behavior" 50 : 873-880, 1993

37 Di Carlo A, "Frequency of stroke in Europe: A collaborative study of population-based cohorts. ILSA Working Group and the Neurologic Diseases in the Elderly Research Group. Italian Longitudinal Study on Aging" 54 (54): S28-S33, 2000

38 Kramer JH, "Executive dysfunction in subcortical ischaemic vascular disease" 72 : 217-220, 2002

39 Lockwood KA, "Executive dysfunction in geriatric depression" 159 : 1119-1126, 2002

40 Duke LM, "Executive control functions in degenerative dementias: a comparative review" 10 : 75-99, 2000

41 Royall DR, "Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association" 14 : 377-405, 2002

42 Grigsby J, "Executive cognitive abilities and functional status among community-dwelling older persons in the San Luis Valley Health and Aging Study" 46 : 590-596, 1998

43 Lincoln NB, "Evaluation of cognitive behavioural treatment for depression after stroke: a pilot study" 11 : 114-122, 1997

44 Robinson RG, "Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial" 299 : 2391-2400, 2008

45 Jorge RE, "Escitalopram and enhancement of cognitive recovery following stroke" 67 : 187-196, 2010

46 Fruehwald S, "Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up" 250 : 347-351, 2003

47 Cui X, "Does depression precede or follow executive dysfunction? Outcomes in older primary care patients" 164 : 1221-1228, 2007

48 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders. 4th ed" American Psychiatric Association 1994

49 Bour A, "Depressive symptoms and executive functioning in stroke patients: a follow-up study" 26 : 679-686, 2011

50 Pariel-Madjlessi S, "Depression: an underrated consequence of stroke in elderly" 3 : 7-16, 2005

51 Melkas S, "Depression-executive dysfunction syndrome relates to poor poststroke survival" 18 : 1007-1016, 2010

52 Connor TJ, "Depression, stress and immunological activation: the role of cytokines in depressive disorders" 62 : 583-606, 1998

53 Carson AJ, "Depression after stroke and lesion location: a systematic review" 356 : 122-126, 2000

54 Wade DT, "Depressed mood after stroke. A community study of its frequency" 151 : 200-205, 1987

55 Elenkov IJ, "Cytokine dysregulation, inflammation and well-being" 12 : 255-269, 2005

56 Devinsky O, "Contributions of anterior cingulate cortex to behaviour" 118 (118): 279-306, 1995

57 Radanovic M, "Contribution to the evaluation of language disturbances in subcortical lesions: a pilot study" 62 : 51-57, 2004

58 Bondareff W, "Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life" 157 : 729-736, 2000

59 Rasquin SM, "Cognitive-behavioural intervention for depression after stroke: five single case studies on effects and feasibility" 19 : 208-222, 2009

60 Lincoln NB, "Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial" 34 : 111-115, 2003

61 Alexopoulos GS, "Clinical presentation of the “depression-executive dysfunction syndrome” of late life" 10 : 98-106, 2002

62 de Groot JC, "Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study" 47 : 145-151, 2000

63 Williams LS, "Care management of poststroke depression: a randomized, controlled trial" 38 : 998-1003, 2007

64 Müller N, "COX-2 inhibition in schizophrenia and major depression" 14 : 1452-1465, 2008

65 Morris PL, "Association of depression with 10-year poststroke mortality" 150 : 124-129, 1993

66 Rasmussen A, "A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients" 44 : 216-221, 2003

67 Aben I, "A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction" 74 : 581-585, 2003